Clinical Trials Logo

Clinical Trial Summary

Retrobulbar optic neuritis (NORB) is the damage to the optic nerve caused by inflammation. It causes a rapidly progressive and painful visual loss, often among young subjects. Diagnosis confirmation is important to start proper treatment, because a NORB is often the first symptom of multiple sclerosis. This diagnosis, based on a set of arguments, is difficult to define by a non-expert ophthalmologist.

The pupillary light reflex is a way to test the visual afferent pathways. If it is subject to a large inter-individual variability, the dynamics of the pupillary light reflex and its latency are more reproducible. An easy way to study the dynamics of the pupillary light reflex is to study the pupillary cycle time (PCT). In the case of NORB, elongation of the conduction in the visual afferent pathways related to demyelination plate increases the latency of the pupillary light reflex and decreases the frequency of the PCT.

Our hypothesis is that PCT dynamics measures would be a reliable indicator and easy to evaluate some pathologies affecting the integrity of the nerve. The validation of a decrease in the frequency of the PCT in NORB, compared to the frequency observed in subjects ophthalmological or neurological disease, could help developing methods to study the conduction of the visual pathways with portable devices used during the standard ophthalmologic consultation and quickly orientate patients to specialized centers.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02894281
Study type Observational
Source Fondation Ophtalmologique Adolphe de Rothschild
Contact
Status Completed
Phase N/A
Start date June 2016
Completion date June 30, 2017

See also
  Status Clinical Trial Phase
Unknown status NCT00261326 - Simvastatin Treatment of Patients With Acute Optic Neuritis Phase 3
Active, not recruiting NCT03963310 - Optical Coherence Tomography and Optic Neuritis Not Related to Multiple Sclerosis
Recruiting NCT03586557 - Effectiveness of Plasma Exchange in Treating With Severe Acute AQP4-Ab Positive Optic Neuritis N/A
Recruiting NCT05487989 - VIsual Pathways Model in Neuro-inflammatory Disorders
Terminated NCT04131764 - Diagnosis of ON With or Without MS or NMOSD
Not yet recruiting NCT06453694 - Efgartigimod for the Treatment of Acute Optic Neuritis Phase 2
Completed NCT01962571 - Treatment of Optic Neuritis With Erythropoietin: a Randomised, Double-blind, Placebo-controlled Trial Phase 3
Recruiting NCT03302585 - High-Dose Vitamin D Induction in Optic Neuritis Phase 2
Recruiting NCT02886377 - The Correlation Between AQP-4 Ab and the Visual Function of Patients With Demyelinating ON at Onset N/A
Completed NCT01987167 - Defining the Functional and Neuro-Protective Potential of ACTHAR in Acute Optic Neuritis Early Phase 1
Completed NCT01451593 - Neuroprotection With Phenytoin in Optic Neuritis Phase 2
Completed NCT03630497 - BN201 SAD MAD Study in Healthy Subjects Phase 1
Completed NCT01337986 - Ampyra for Optic Neuritis in Multiple Sclerosis Phase 2/Phase 3
Completed NCT01274702 - Visual Reconstitution Therapy After Optic Neuritis Phase 2
Active, not recruiting NCT00445367 - Biobank For MS And Other Demyelinating Diseases
Withdrawn NCT00037115 - Induction Therapy With a Single High Dose Bolus of Intravenous Methotrexate With Leucovorin Rescue, Prior to Initiation of AVONEX® Treatment, in Patients Presenting With a First Acute Demyelinating Event. Phase 4
Not yet recruiting NCT06389968 - Light Stimulation to Improve Visual Function After Optic Neuritis in Persons With Multiple Sclerosis N/A
Recruiting NCT04257734 - Epidemiologic and Clinical Characteristics of Optic Neuritis in China
Completed NCT03753893 - Ocular Manifestations in Rheumatic Diseases
Completed NCT02939937 - Effect of Phenytoin on the Ganglion Cell Layer in Patients With Optic Neuritis Phase 2